Wang Shengli, Zhang Mingyue, Li Tao, Chen Xinru, Wu Qinhan, Tian Dan, Granot Zvi, Xu Hongbiao, Hao Jianlei, Zhang Hongru
Zhuhai Institute of Translational Medicine, Zhuhai People's Hospital Affiliated with Jinan University, 79 Kangning Rd, Zhuhai, 519000, Guangdong, P.R. China.
Biomedical Translational Research Institute, Faculty of Medical Science, Jinan University, 601 W Huangpu Ave, Guangzhou, 510632, Guangdong, P.R. China.
J Leukoc Biol. 2024 Dec 31;117(1). doi: 10.1093/jleuko/qiae030.
Poly (ADP-ribose) polymerase family member 11 (PARP11) has important immune regulatory functions in viral infection and tumor immune response. Particularly, PARP11 showed protumor activities in multiple preclinical murine models. However, no systematic pan-cancer analysis has been conducted to explore PARP11 function. In this study, we used multiple databases to assess PARP11 expression, which is associated with clinical outcomes, immune checkpoint factors, prognostic significance, genomic characteristics, and immunological aspects. The analysis revealed varying expression levels of PARP11 across different cancer types and a significant correlation between its expression and immune cell infiltration. Insights from the CellMiner database suggest a strong link between PARP11 expression and sensitivity to anticancer drugs, highlighting its potential as a therapeutic target. Moreover, PARP11 expression correlates with patient survival during anti-PD1 and anti-CTLA4 treatments, suggesting that PARP11 would be a predictor of immune checkpoint inhibitor treatment. In summary, PARP11 would be a potential immunoregulatory target and a diagnosis and prognosis marker for certain types of cancers. The detailed mechanisms of PARP11 in tumor immune responses need to be further investigated.
聚（ADP - 核糖）聚合酶家族成员11（PARP11）在病毒感染和肿瘤免疫反应中具有重要的免疫调节功能。特别是，PARP11在多个临床前小鼠模型中表现出促肿瘤活性。然而，尚未进行系统的泛癌分析来探索PARP11的功能。在本研究中，我们使用多个数据库评估PARP11的表达，其与临床结果、免疫检查点因子、预后意义、基因组特征和免疫学方面相关。分析揭示了PARP11在不同癌症类型中的表达水平各异，且其表达与免疫细胞浸润之间存在显著相关性。来自CellMiner数据库的见解表明PARP11表达与抗癌药物敏感性之间存在紧密联系，凸显了其作为治疗靶点的潜力。此外，PARP11表达与抗PD1和抗CTLA4治疗期间的患者生存率相关，表明PARP11可能是免疫检查点抑制剂治疗的预测指标。总之，PARP11可能是一种潜在的免疫调节靶点以及某些类型癌症的诊断和预后标志物。PARP11在肿瘤免疫反应中的详细机制有待进一步研究。
